Taking A Bold Path To Improve Fibrosis Prognosis

Agomab Is Targeting Two Growth Factor Pathways Which Could Help To Modify Disease Outcomes

 
• By Chloe Kent

Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.  

Fibrosis
• Source: Shutterstock

More from Rising Leaders

More from Leadership